Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) has been implicated in control of cell proliferation and oncogenesis in many cancers and, as such, has been identified as a therapeutic target 11. The gene discussed is NFKB1; the disease is cancer.